- Sanrai International appointed to promote, market and sell ResAppDx in emerging markets
- Sanrai is a distributor of innovative medical device products to emerging markets and has long-standing relationships in more than 50 markets
- Agreement covers countries in Africa, the Middle East, South America, South Asia, Central America and the Caribbean with a total population of around 3 billion people
- Majority of use is expected to be with in-clinic ResAppDx
Brisbane, Australia, 22 December 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, has entered into a three-year distribution agreement with Sanrai International (“Sanrai”). Sanrai will distribute ResAppDx through its network of offices and distributors covering emerging markets. Sanrai will be a preferred distributor in the majority of these countries, except in major markets such as India, Mexico and Brazil.
Sanrai is headquartered in New York and has a network of regional offices and partners in Latin America, Africa, the Middle East and South Asia. Sanrai has long-standing relationships in more than 50 countries and is continually growing its network of customers and distributors. Sanrai’s goal is to transform healthcare around the world by making the access to innovative medical technology equitable no matter where you are.
ResAppDx uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone’s built-in microphone. It is CE Marked in Europe and TGA approved for ARTG listing in Australia. ResApp will work with Sanrai to obtain regulatory approvals in additional countries, where required. It is anticipated that the majority of the use will be in-clinic.
Jaspreet Rai, CEO of Sanrai said: “Our mission is to partner with providers, ministries of health, regulatory bodies, and hospital groups to empower medical suppliers to launch products focusing on what matters most – to better the lives of patients needing innovative solutions to be locally available to survive and thrive. We are excited about the potential of ResAppDx to increase the diagnostic quality in emerging markets, to improve, and save lives.”
CEO and Managing Director of ResApp, Dr Tony Keating said: “We are excited to partner with Sanrai who will provide significant reach and scale in emerging markets. This deal supports one of our core values of health equity – bringing this important technology to those who need it the most. Sanrai’s experience in delivering in emerging markets will be an important part of our future growth plans for the benefit of the 3 billion people who live in these countries.”
About Sanrai International
Sanrai International is a medical device distribution company focused on bringing innovative products into the emerging markets with partners in more than 50 countries. With offices in Latin America, Africa, the Middle East, and Southeast Asia, Sanrai focuses on training, technical support, education, logistics, after sales service, and more to make access to innovation available in the hardest to reach markets. Sanrai carries more than 100 devices and 600 consumables with a focus on respiratory, neonatal, orthopaedic, sleep, and diagnostic therapeutic classes, manufactured in more than 10 countries. Our mission is to minimize the gap in healthcare between countries by developing the infrastructure needed to successfully support our partners on the ground to sustainably supply innovative medical devices for the long term. For more information, please visit www.sanrai.com
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.